healthcare

healthcare Articles

Corvus Pharmaceuticals shares were sharply higher on Monday after the company announced updated data from its ongoing early-stage study in patients with COVID-19.
MyoKardia shares hit an all-time high early on Monday after it was announced that Bristol-Myers Squibb would be acquiring the company.
If the marijuana legalization ballot measures being voted on in five states next month are all approved, total marijuana sales could reach $35 billion by 2025.
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
Solid Biosciences shares more than doubled on Thursday after the company announced a key update from the FDA.
Compared to the office and retail real estate investment trusts, which have been hit hard during the pandemic, the medical office REITs have held up extremely well, and investors are starting to...
Moderna and Regeneron Pharmaceuticals each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
Aptorum shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious diseases.
Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH). This agreement is ultimately for Genfit’s technology to...
Eiger BioPharmaceuticals has announced disappointing results from a study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.
Aquestive Therapeutics said that it had received a negative response from the FDA concerning its treatment for the management of seizure clusters.
Things aren’t looking up for Inovio Pharmaceuticals, after the FDA notified the company that it was placing a partial hold on its COVID-19 vaccine study.
These five high-conviction health care stock picks from the analysts at Jefferies all make sense for investors looking to gain exposure to a sector that should continue to do well the rest of 2020...
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Credit Suisse has set an Outperform rating and $290 price target on Amgen shares. That target implies more than 20% upside to the stock's recent trading price.